Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 (Enlonstobart) plus Nab-Paclitaxel in Advanced TNBC
NCT05068141Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308 in triple-negative breast cancer (TNBC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
PBI-1308
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05068141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068141.